{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:45:24Z","timestamp":1761662724126},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T00:00:00Z","timestamp":1232064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s10620-008-0683-2","type":"journal-article","created":{"date-parts":[[2009,1,15]],"date-time":"2009-01-15T17:03:03Z","timestamp":1232038983000},"page":"2699-2705","source":"Crossref","is-referenced-by-count":34,"title":["Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection"],"prefix":"10.1007","volume":"54","author":[{"given":"Hesham M.","family":"Elgouhari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia O.","family":"Zein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Hanouneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel E.","family":"Feldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar N.","family":"Zein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,16]]},"reference":[{"key":"683_CR1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0168-8278(05)80631-2","volume":"21","author":"ME Allison","year":"1994","unstructured":"Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21:1135\u20131139. doi: 10.1016\/S0168-8278(05)80631-2 .","journal-title":"J Hepatol"},{"key":"683_CR2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/hep.510300416","volume":"30","author":"S Caronia","year":"1999","unstructured":"Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;30:1059\u20131063. doi: 10.1002\/hep.510300416 .","journal-title":"Hepatology"},{"key":"683_CR3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/75.4.355","volume":"75","author":"H Knobler","year":"2000","unstructured":"Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in non-cirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355\u2013359.","journal-title":"Mayo Clin Proc"},{"key":"683_CR4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.510290235","volume":"29","author":"AL Mason","year":"1999","unstructured":"Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328\u2013333. doi: 10.1002\/hep.510290235 .","journal-title":"Hepatology"},{"key":"683_CR5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/jhep.2001.0103306le01","volume":"33","author":"SH Mehta","year":"2001","unstructured":"Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology. 2001;33:1554. doi: 10.1053\/jhep.2001.0103306le01 .","journal-title":"Hepatology"},{"key":"683_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1572-0241.2005.40429.x","volume":"100","author":"CO Zein","year":"2005","unstructured":"Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100:48\u201355. doi: 10.1111\/j.1572-0241.2005.40429.x .","journal-title":"Am J Gastroenterol"},{"key":"683_CR7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8278(00)80065-3","volume":"32","author":"NN Zein","year":"2000","unstructured":"Zein NN, Abdulkarim AS, Wiesner RH, et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32:209\u2013217. doi: 10.1016\/S0168-8278(00)80065-3 .","journal-title":"J Hepatol"},{"key":"683_CR8","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.2337\/dc06-0456","volume":"29","author":"R Simo","year":"2006","unstructured":"Simo R, Lecube A, Genesca J, et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29:2462\u20132466. doi: 10.2337\/dc06-0456 .","journal-title":"Diabetes Care"},{"key":"683_CR9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0168-8278(03)00456-2","volume":"39","author":"V Ratziu","year":"2003","unstructured":"Ratziu V, Munteanu M, Charlotte F, et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. 2003;39:1049\u20131055. doi: 10.1016\/S0168-8278(03)00456-2 .","journal-title":"J Hepatol"},{"key":"683_CR10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gut.2004.052167","volume":"54","author":"JA Davila","year":"2005","unstructured":"Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533\u2013539. doi: 10.1136\/gut.2004.052167 .","journal-title":"Gut"},{"key":"683_CR11","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","volume":"5","author":"GN Ioannou","year":"2007","unstructured":"Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5:938\u2013945.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"683_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.21455","volume":"45","author":"HS Conjeevaram","year":"2007","unstructured":"Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80\u201387. doi: 10.1002\/hep.21455 .","journal-title":"Hepatology"},{"key":"683_CR13","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1572-0241.2005.41403.x","volume":"100","author":"R D\u2019Souza","year":"2005","unstructured":"D\u2019Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005;100:1509\u20131515. doi: 10.1111\/j.1572-0241.2005.41403.x .","journal-title":"Am J Gastroenterol"},{"key":"683_CR14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1053\/j.gastro.2004.11.016","volume":"128","author":"S Dharancy","year":"2005","unstructured":"Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128:334\u2013342. doi: 10.1053\/j.gastro.2004.11.016 .","journal-title":"Gastroenterology"},{"key":"683_CR15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1872-034X.2007.00052.x","volume":"37","author":"I Konishi","year":"2007","unstructured":"Konishi I, Horiike N, Hiasa Y, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2007;37:331\u2013336. doi: 10.1111\/j.1872-034X.2007.00052.x .","journal-title":"Hepatol Res"},{"key":"683_CR16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","volume":"128","author":"M Romero-Gomez","year":"2005","unstructured":"Romero-Gomez M, Del MV, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636\u2013641. doi: 10.1053\/j.gastro.2004.12.049 .","journal-title":"Gastroenterology"},{"key":"683_CR17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2003.11.056","volume":"126","author":"Y Shintani","year":"2004","unstructured":"Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840\u2013848. doi: 10.1053\/j.gastro.2003.11.056 .","journal-title":"Gastroenterology"},{"key":"683_CR18","doi-asserted-by":"crossref","first-page":"G722","DOI":"10.1152\/ajpgi.00411.2003","volume":"286","author":"CK Sung","year":"2004","unstructured":"Sung CK, She H, Xiong S, et al. Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2004;286:G722\u2013G729. doi: 10.1152\/ajpgi.00411.2003 .","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"683_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1098-3597(98)90014-X","volume":"1","author":"JR Gavin III","year":"1998","unstructured":"Gavin JR III. New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone. 1998;1:1\u201312. doi: 10.1016\/S1098-3597(98)90014-X .","journal-title":"Clin Cornerstone"},{"key":"683_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207\u2013214. doi:10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.","journal-title":"Cancer"},{"key":"683_CR21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","volume":"19","author":"KP Batts","year":"1995","unstructured":"Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409\u20131417.","journal-title":"Am J Surg Pathol"},{"key":"683_CR22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/gut.2004.050302","volume":"54","author":"L Fartoux","year":"2005","unstructured":"Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54:1003\u20131008. doi: 10.1136\/gut.2004.050302 .","journal-title":"Gut"},{"key":"683_CR23","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.3748\/wjg.v12.i44.7075","volume":"12","author":"M Romero-Gomez","year":"2006","unstructured":"Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075\u20137080.","journal-title":"World J Gastroenterol"},{"key":"683_CR24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/gast.2003.50018","volume":"124","author":"MG Ghany","year":"2003","unstructured":"Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97\u2013104. doi: 10.1053\/gast.2003.50018 .","journal-title":"Gastroenterology"},{"key":"683_CR25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep.21078","volume":"43","author":"P Perumalswami","year":"2006","unstructured":"Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780\u2013787. doi: 10.1002\/hep.21078 .","journal-title":"Hepatology"},{"key":"683_CR26","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.21239","volume":"43","author":"MR Charlton","year":"2006","unstructured":"Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43:1177\u20131186. doi: 10.1002\/hep.21239 .","journal-title":"Hepatology"},{"key":"683_CR27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cct.2004.08.003","volume":"25","author":"WM Lee","year":"2004","unstructured":"Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. Control Clin Trials. 2004;25:472\u2013492. doi: 10.1016\/j.cct.2004.08.003 .","journal-title":"Control Clin Trials"},{"key":"683_CR28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/498512","volume":"42","author":"BL Pearlman","year":"2006","unstructured":"Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis. 2006;42:82\u201391. doi: 10.1086\/498512 .","journal-title":"Clin Infect Dis"},{"key":"683_CR29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u2013982. doi: 10.1056\/NEJMoa020047 .","journal-title":"N Engl J Med"},{"key":"683_CR30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958\u2013965. doi: 10.1016\/S0140-6736(01)06102-5 .","journal-title":"Lancet"},{"key":"683_CR31","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","volume":"350","author":"AJ Muir","year":"2004","unstructured":"Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265\u20132271. doi: 10.1056\/NEJMoa032502 .","journal-title":"N Engl J Med"},{"key":"683_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0009-9120(01)00213-2","volume":"34","author":"MG Neuman","year":"2001","unstructured":"Neuman MG, Blendis LM, Shear NH, et al. Cytokine network in non-responding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. Clin Biochem. 2001;34:183\u2013188. doi: 10.1016\/S0009-9120(01)00213-2 .","journal-title":"Clin Biochem"},{"key":"683_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0024-3205(00)00622-6","volume":"67","author":"JC Pickup","year":"2000","unstructured":"Pickup JC, Chusney GD, Thomas SM, et al. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291\u2013300. doi: 10.1016\/S0024-3205(00)00622-6 .","journal-title":"Life Sci"},{"key":"683_CR34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/clim.2002.5288","volume":"105","author":"G Taliani","year":"2002","unstructured":"Taliani G, Badolato MC, Nigro G, et al. Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C. Clin Immunol. 2002;105:279\u2013285. doi: 10.1006\/clim.2002.5288 .","journal-title":"Clin Immunol"},{"key":"683_CR35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","volume":"42","author":"NN Zein","year":"2005","unstructured":"Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315\u2013322. doi: 10.1016\/j.jhep.2004.11.025 .","journal-title":"J Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-008-0683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-008-0683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-008-0683-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:42:46Z","timestamp":1559230966000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-008-0683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,16]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s10620-008-0683-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,16]]}}}